Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Agios Pharmaceuticals (AGIO) over the last 13 years, with Q4 2025 value amounting to 608.89%.

  • Agios Pharmaceuticals' EBIT Margin rose 5564100.0% to 608.89% in Q4 2025 from the same period last year, while for Dec 2025 it was 873.87%, marking a year-over-year increase of 2926000.0%. This contributed to the annual value of 873.87% for FY2025, which is 2926000.0% up from last year.
  • Latest data reveals that Agios Pharmaceuticals reported EBIT Margin of 608.89% as of Q4 2025, which was up 5564100.0% from 907.37% recorded in Q3 2025.
  • In the past 5 years, Agios Pharmaceuticals' EBIT Margin ranged from a high of 608.89% in Q4 2025 and a low of 12156.85% during Q1 2022
  • Its 4-year average for EBIT Margin is 2068.27%, with a median of 1295.97% in 2023.
  • Its EBIT Margin has fluctuated over the past 5 years, first soared by 105413600bps in 2023, then crashed by -976300bps in 2025.
  • Agios Pharmaceuticals' EBIT Margin (Quarter) stood at 2300.97% in 2022, then soared by 35bps to 1496.23% in 2023, then rose by 22bps to 1165.3% in 2024, then surged by 48bps to 608.89% in 2025.
  • Its EBIT Margin was 608.89% in Q4 2025, compared to 907.37% in Q3 2025 and 1020.12% in Q2 2025.